ReviewCureus2025
Artificial Intelligence Applications in the Prediction and Management of Pediatric Asthma Exacerbation: A Systematic Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric asthma exacerbations remain a significant global health challenge due to their unpredictable nature and potential for severe morbidity. While artificial intelligence (AI) shows promise in improving prediction and management, the evidence base is fragmented. This systematic review synthesizes current literature on AI applications for pediatric asthma exacerbation prediction and management, evaluating model performance, clinical utility, and methodological quality. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, we searched PubMed, Scopus, Elsevier, Web of Science, and Excerpta Medica Database (Embase) (2020-2025) for studies applying AI/machine learning (ML) to pediatric asthma exacerbations. Eight studies met the inclusion criteria after screening 431 records. Data were extracted on study design, AI models, input features, outcomes, and performance metrics. Risk of bias was assessed using Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) for non-randomized studies and the Cochrane Risk of Bias 2 (RoB 2) tool for randomized trials. Eight studies demonstrated AI's effectiveness in predicting pediatric asthma exacerbations, outperforming traditional methods. Performance varied, with multimodal data yielding the best results. Some models faced limitations from data biases or small samples. Most studies had a low risk of bias. AI showed potential to improve clinical workflows, but real-world impact needs more research. AI shows strong potential for pediatric asthma exacerbation prediction, particularly with multimodal data. Key challenges include algorithmic bias mitigation, prospective validation, and standardization of outcome metrics. Future research should prioritize equitable model development and clinical integration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.